1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
LOI deadline June 4, 2026; full application deadline September 16, 2026; funding decisions December 2026. Stored deadline of 2026-06-05 corresponds to LOI step, not the final full proposal deadline.
"Investigator-Initiated Clinical Trials Program" is currently closed and not accepting applications.
Investigator-Initiated Clinical Trials Program is sponsored by Canadian Cancer Society (in partnership with Cancer Research Society). This program supports investigator-initiated clinical trials in cancer research across Canada. While the specific focus on cervical cancer compassionate screening is not explicitly stated, clinical trials related to cancer prevention, detection, and treatment are highly relevant.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Investigator-Initiated Clinical Trials Program | Canadian Cancer Society 2026 Clinical Trials Program Investigator-Initiated Clinical Trials Program 2026 Clinical Trials Program The Cancer Research Society (CRS), with the Canadian Cancer Society (CCS) and the Terry Fox Research Institute (TFRI), are launching a new funding opportunity dedicated entirely to investigator-initiated oncology clinical trials in Canada.
With partners - the Lotte & John Hecht Memorial Foundation, Génome Québec, Kindred Foundation and Childhood Cancer Canada - this program aims to enable Canadian researchers to lead groundbreaking trials that can reshape the cancer landscape in Canada and worldwide. Learn more about the funding opportunity CCS has historically demonstrated a strong commitment to advancing research aimed at saving and improving lives.
Clinical trials play a critical role in translating research findings into practical care and viable treatment options.
For this funding opportunity, CCS and its partners will fund early-stage clinical trials (from proof-of-concept to Phase II) focused in the following areas: Low survival and high incidence cancers, specifically: lung, esophageal, stomach, brain*, liver, ovarian, pancreas, prostate, breast, and/or colorectal cancer – with a goal of developing novel detection approaches/modalities and/or treatments *Specific partnered funds are available for trials focused on glioblastoma Prevention of cancer, especially for high incidence cancers such as prostate, breast, colorectal and/or lung cancer.
As a result of partnership funding, trials utilizing gold – as a diagnostic, drug delivery vehicle, and/or therapeutic enhancer – with a strong potential to improve patient outcomes, influence clinical practice, or advance therapeutic pathways. Successful applicants funded by the Canadian Cancer Society must adhere to CCS’s research funding policies. More information is available here .
May 1, 2026 (12 to 1 pm EST) Letter of intent deadline: June 4, 2026 (11:59 pm EST) September 16, 2026 (11:59 pm EST) To reflect the diversity of investigator-initiated clinical research, the program will support two funding streams: Proof-of-Concept Trials: Early-stage exploratory clinical studies aimed at demonstrating feasibility and generating preliminary data Full-Scale Clinical Trials: Advanced clinical trials with the potential to influence clinical guidelines or standards of care In its inaugural edition, the program will invest up to $25 million to advance clinical trials across Canada.
CCS has a tentative funding envelope of $9 million for the program. Full-Scale Clinical Trials
According to the current listing, eligibility includes: Canadian researchers at eligible institutions; two streams available: Proof-of-Concept Trials ($500K/3 years) and Full-Scale Clinical Trials ($2M/5 years). Total program investment up to $25 million nationally. Confirm the full requirements in the official notice before applying.
The current listing shows $2,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 16, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Investigator-Initiated Clinical Trials Program is funded by Canadian Cancer Society (in partnership with Cancer Research Society). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Gates Foundation committed at least $1 billion over two years to equitable AI alongside its 10th Goalkeepers Report — 40% education, 40% health, 10% agriculture, 10% digital infrastructure. Five days later, 60 organizations signed a five-year goal to reach 3.4 billion speakers of underrepresented languages. Here is how implementing nonprofits should read both.
Read articleNEA's FY2027 Partnership Agreement Grants (2027NEA04PA) put $59 million into 56 state arts agencies with a September 29, 2026 deadline. No individual arts nonprofit can apply. But this is the channel through which most NEA dollars actually reach small organizations — and the supplanting rule and 1-to-1 state cost share determine how much reaches yours.
Read articleDARPA's DIAL program already had AI rediscover the Kalman filter and wavelets from scratch. SPEED DIAL (DPA26TZ05-DV003) funds the unglamorous next step: turning algorithm discovery into a tool that plugs into MATLAB, Simulink, and COMSOL. Up to $750,000 base plus a $1.25 million option, Direct to Phase II only, with a three-accomplishment feasibility gate and a mandatory university partner. Here is the milestone schedule, the interpretability requirement, and who is actually eligible.
Read article